Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial.
Harpreet S BajajItamar RazOfri MosenzonSabina A MurphyAliza RozenbergIlan YanuvDeepak L BhattLawrence Alan LeiterDarren K McGuireJohn P H WildingIngrid A M Gause-NilssonMarc S SabatineStephen D WiviottAvivit CahnPublished in: Diabetes, obesity & metabolism (2020)
Dapagliflozin reduced the risk of CVD/HHF consistently, regardless of diabetes duration, whereas the treatment effect for MACE differed by duration subgroups, with significant reductions with dapagliflozin in patients with long-standing diabetes.